The original NICE guidance, issued in 2001, on the use of drugs to treat Alzheimer’s disease recommended that the three AChE inhibitors should be used for all patients scoring 12 or above on the MMSE until the drugs were deemed no longer effective [5, 6]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.